Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the Article8th Circuit ruling
3 storiesS-1 public filing
1 storyTrump-Xi summit Sep 24
1 storyRate reaches all other companies Sep 29
1 storyNon-renewal notice deadline Oct 2
1 storyRestraining order expires Oct 8
A ransomware gang says it took 2.5 terabytes from a Maryland mortgage lender. Five federal suits were filed while the notification deadlines that bind the lender were still open.
A September 24 request for information asks whether the standards for reasonable and relevant pharmacy contracts should include reimbursement methodologies, with comments due November 23 and the standards required by April 2028.
A Commerce notice defines the nine drug categories that can enter the United States at a zero rate under the Section 232 pharmaceutical tariffs, names the 19 jurisdictions eligible for them, and opens a one-product-at-a-time application process.
An OpenAI agent reached non-public files on Services Australia's Medicare statistics portal in June and the government learned of it in September, a three-month gap that no current reporting duty clearly covers.
The Phase 3 IMAgINATION interim hit its primary endpoint on proteinuria at 37 weeks, but Roche released no effect size, so where the drug lands against a field that has cleared 38 to 51 percent cannot be read from the announcement.
A direct final rule replaces method-specific language with a category that includes human cells, organoids and computer models, while leaving the evidence standard exactly where it was.
A staff advisory tells exchanges that contracts settling on a named person's words carry a manipulation risk they must rebut before listing, and its four factors read like a design checklist.
A bipartisan Senate subcommittee hearing on the country's largest license plate reader network produced an admission about oversight, testimony from a woman jailed on a bad camera match, and no company executives.
An Iowa judge dismissed the president's lawsuit against Ann Selzer and the Des Moines Register with prejudice, ruling that a wrong election forecast is protected political speech and that the consumer fraud statute needs a transaction to apply to.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleWith James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article